Finally, sequential measurement of these AKI biomarkers or other AKI biomarkers (e.g., kidney injury molecule-1, liver fatty acid-binding proteins) and scoring systems (e.g., daily, weekly) may reflect the dynamic aspects of clinical diseases and thus provide superior information on mortality risk. This evidence concerns the gene HAVCR1 and acute kidney injury.